The effects of thyroid hormones and antithyroid treatment upon lumbar spine bone mineral content (lumbar BMC) were studied in a consecutive series of patients with myxoedema and thyrotoxicosis, respectively. All patients were investigated in the untreated state and 3-monthly during appropriate treatment for 1 year by using dual-photon [153Gd] absorptiometry. Patients with myxoedema (n = 8) did not differ from normal individuals as regards initial lumbar BMC, but levothyroxine-treatment caused significant reduction in this variable. The median decrease in lumbar BMC after 1 year was 8.9% (95% confidence limits 1.5-15.4%, P less than 0.05). This loss of bone might be attributed to an inappropriate increase in bone turnover in the euthyroid state. It is as yet uncertain whether it predisposes to spinal osteopenia. Median lumbar BMC in patients with thyrotoxicosis (n = 25) was 12.6% (2.0-16.6%, P less than 0.05) lower than that of normal individuals before the beginning of treatment. Lumbar BMC increased during antithyroid therapy. The median gain in bone mineral after 1 year was 3.7% (1.6-9.6%, P less than 0.01). These findings suggest that excess of thyroid hormones leads to negative spinal bone mineral balance. The revealed bone loss was clinically insignificant, however, and it appeared to be at least partially reversible after antithyroid treatment.

No abstract

The programme evaluation data is used to show that it has had an impact on the knowledge and skills of the bed managers involved, but also on their subsequent behaviours. These changes have translated into results for the organization and the individual, including staff retention, promotion and fewer cancelled operations. We conclude that the programme is an effective way to enhance the knowledge and skills of bed managers, and that the enhanced profile of bed management raises challenges for nurse managers in many areas of the organization.

No abstract

We identified 46 patients with a history of partial seizures, with and without secondarily generalization, who received levetiracetam (LEV) (Keppra) monotherapy. Patients began LEV either as first line therapy (n=11) or were converted to LEV monotherapy (n=35) after failing prior antiepileptic medications (AEDs). Patients were followed up to 12 months after LEV started. The majority of these patients were able to continue on LEV and a small number of patients discontinued LEV secondary to lack of efficacy. One third of the non-seizure free group at 6 months of follow-up had worse seizure control at 12 months and two thirds had the same or better seizure control. Our 1-year follow-up data of LEV as monotherapy suggests that LEV can be effective and well tolerated in adults with either new or difficult to control epilepsy. A prospective, large, long-term double-blind study is needed to confirm this finding.